176P - ALK-rearranged non-small cell lung cancer is associated with a high rate of venous thromboembolism

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Thoracic Malignancies
Presenter Alona Zer
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors A. Zer1, A. Hershko-Klement2, D. Hwang3, G. Korpanty4, N. Leighl4, G. Liu5, R. Feld6, R. Burkes7, M. Tsao8, F. Shepherd4
  • 1Medical Oncology, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, 49100 - Petach Tikva/IL
  • 2Fertility, Meir Medical Center, 49100 - Kfar Saba/IL
  • 3Pathology, Princess Margaret Hospital, Toronto/CA
  • 4Medical Oncology, Princess Margaret Hospital, M5G 2M9 - Toronto/CA
  • 5Medical Oncology, Princess Margaret Hospital, M5G 2M9 - Toronto/CA
  • 6Dept. Of Medical Oncology And Hematology, Princess Margaret Hospital, M5G 2M9 - Toronto/CA
  • 7Medicine, Mount Sinai Hospital, M5G 1X5 - Toronto/CA
  • 8Pathology, Princess Margaret Hospital, M5G 2M9 - Toronto/CA



Patients with lung cancer are at increased risk for venous thromboembolism (VTE), particularly those receiving chemotherapy. It is estimated that 8–15% of patients with advanced non-small cell lung cancer (NSCLC) experience a VTE in the course of their disease. The incidence in patients with specific molecular subtypes of NSCLC is unknown. We undertook this review to determine the incidence of VTE in patients with ALK-rearranged NSCLC.


We identified all patients with ALK-rearranged NSCLC, diagnosed and/or treated at the Princess Margaret Cancer Centre (PM CC) between July2012 and January 2015. Retrospective data were extracted from electronic medical records.


Among 55 patients with ALK-rearranged NSCLC, 26 were male and 29 female, with a median age of 65 years; 66% were stage IV at diagnosis, and 15% developed metastatic disease after diagnosis. At a median follow-up of 22 months, 23 (42%) experienced VTE. VTE occurred during treatment with tyrosine kinase inhibitors (TKIs) in 39% of cases and during chemotherapy in 18%. Patients with VTE were more likely to be Caucasian (p = 0.006). The occurrence of VTE was associated with a trend towards worse prognosis (overall survival HR = 2.88, p = 0.059).


We found the rate of VTE in our ALK-rearranged cohort is 3–5-fold higher than previously reported for the general NSCLC population. This warrants confirmation in larger cohorts.

Clinical trial identification

Legal entity responsible for the study



Princess Margaret Cancer Center


All authors have declared no conflicts of interest.